Clinical trials
Metastatic Breast Cancer clinical trials
Below are recruiting metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 1,312 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Phoenix, ArizonaAges 18 years+ - NCT06064812RecruitingPhase 1/Phase 2
Testing a new drug for advanced ER-positive breast cancer
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
Hefei, AnhuiAges 18 years+ - NCT04553770RecruitingPhase 2
Trastuzumab deruxtecan with or without anastrozole for early breast cancer
This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.
Fullerton, CaliforniaAges 18 years+ - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT06067503RecruitingPhase 2
PET scan to detect hormone therapy resistance in breast cancer
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
Madison, WisconsinAges 18 years+ - NCT04526587Recruiting
Study of breast cancer markers after CDK4/6 inhibitor treatment
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Buffalo, New YorkAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT04543799Recruiting
Sleep quality study in prostate and early breast cancer patients
This trial studies how sleep quality changes while people with prostate cancer or early breast cancer receive standard treatments. It may help doctors understand which treatment factors affect sleep and identify who might benefit from support for sleep problems.
BellinzonaAges 18 years+ - NCT05800275RecruitingPhase 2
Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
BordeauxAges 18 years+ - NCT05910398RecruitingPhase 3
Extending anti-HER2 treatment after breast cancer surgery
This Phase 3 trial tests whether continuing or pausing the anti-HER2 medicine pyrotinib after surgery can lower the chance that invasive HER2-positive breast cancer comes back. It may help people who have recently finished trastuzumab or T-DM1 and are well enough to take tablets.
ShanghaiAges 18 years+ - NCT06016387RecruitingPhase 2
Drug combo with radiation for HER2+ breast cancer spread to spinal lining
This trial tests a combination of three targeted drugs (tucatinib, trastuzumab, and capecitabine) along with radiation to the brain or spine for people whose HER2-positive breast cancer has spread to the lining of the brain or spinal cord. The goal is to see if this treatment is safe and effective.
Ottawa, OntarioAges 18 years+ - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT05982678RecruitingPhase 2
Study of a drug for breast cancer that has spread to a few spots
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
AmsterdamAges 18 years+ - NCT05982093RecruitingPhase 2
Elacestrant with or without triptorelin for premenopausal breast cancer
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
Badalona, BarcelonaAges 35 years+ - NCT05977036Recruiting
Choosing breast cancer treatment with biomarker testing
This study helps doctors choose the best first or second treatment for breast cancer that has spread or can't be removed. It uses a blood test to look at your cancer's markers, which may help guide which therapy is right for you. The study is for people with HR-positive, HER2-negative breast cancer who are about to start treatment with hormone therapy plus a CDK4/6 inhibitor, or another type of therapy.
St Louis, MissouriAges 18 years+ - NCT05900895RecruitingPhase 1
Estradiol plus olaparib for ER-positive breast cancer
This early-stage study tests whether combining estradiol (a form of estrogen) with olaparib (a targeted cancer medicine) can control ER-positive, HER2-negative breast cancer that has spread or come back. It may help by attacking cancer cells in a new way after standard hormone-based treatments.
Lebanon, New HampshireAges 18 years+ - NCT05964504Recruiting
Registry study for metastatic lobular breast cancer
This study collects health information from adults with invasive lobular breast cancer that has spread (metastatic) to help researchers understand factors linked to survival. Joining may help build better knowledge for future treatments and care planning.
San Diego, CaliforniaAges 18 years+ - NCT05972343Recruiting
Cooling treatment to shrink breast tumors without surgery
This trial tests a cooling-based procedure (called cryoablation) to destroy a breast cancer tumor in people who cannot or do not want surgery. It may help shrink the visible tumor without needing an operating room.
St Louis, MissouriAges 18 years+ - NCT05945732Recruiting
Testing T-DXd or chemo for HER2-low or HR-positive breast cancer
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
GrazAges 18 years+ - NCT05950945RecruitingPhase 3
Trastuzumab deruxtecan for HER2-low metastatic breast cancer
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
Miami Beach, FloridaAges 18 years+ - NCT05919108RecruitingPhase 2
Neratinib before surgery for HER2-mutated invasive lobular breast cancer
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05930483Recruiting
Remote weight loss program for Hispanic/Latina breast cancer survivors
This trial tests a community-style, online (remote) weight loss program for people who finished breast cancer treatment and are now trying to improve health and weight. It may help by supporting safer weight loss through diet/energy reduction and physical activity.
Seattle, WashingtonAges 18 years+ - NCT05914961Recruiting
Tracking inflammation response in triple-negative breast cancer
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
TübingenAges 18 years+ - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Gilbert, ArizonaAges 18 years+
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer?
- Yes. Clin2 currently lists 1,312 recruiting metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Locally Advanced or Metastatic Breast Cancer
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Advanced/Metastatic Breast Cancer
- Non-metastatic Breast Cancer
- Advanced or Metastatic Breast Cancer
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.